MARKET

THAR

THAR

Tharimmune Inc
NASDAQ
2.390
-0.080
-3.24%
After Hours: 2.380 -0.01 -0.42% 19:34 12/05 EST
OPEN
2.470
PREV CLOSE
2.470
HIGH
2.475
LOW
2.360
VOLUME
167.48K
TURNOVER
--
52 WEEK HIGH
9.08
52 WEEK LOW
0.9520
MARKET CAP
83.76M
P/E (TTM)
-0.5816
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at THAR last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at THAR last week (1117-1121)?
Weekly Report · 11/24 09:14
Weekly Report: what happened at THAR last week (1110-1114)?
Weekly Report · 11/17 09:14
Tharimmune Inc. Files Initial Statement of Beneficial Ownership for CEO Mark Wendland
Reuters · 11/14 19:21
Tharimmune Inc. Files Initial Statement of Beneficial Ownership for President Mark Toomey
Reuters · 11/14 19:19
BUZZ-U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APA
Reuters · 11/13 19:09
BUZZ-U.S. STOCKS ON THE MOVE-Firefly Aerospace, Salarius, Spectrum Brands 
Reuters · 11/13 15:56
Tharimmune Shares Drop Premarket Following FDA Feedback on Plan for Lead Clinical Asset
Dow Jones · 11/13 14:23
More
About THAR
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.

Webull offers Tharimmune Inc stock information, including NASDAQ: THAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THAR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading THAR stock methods without spending real money on the virtual paper trading platform.